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Background: Cardio-Oncology is an evolving discipline that focuses on the management of cancer patients who
develop cardiovascular complications as a result of their treatment. Although the current combination of surgical
resection, radiation, and chemotherapy may lead to a cure in cancer patients, the administration of anti-cancer
drugs, in particular Doxorubicin (DOX) and Trastuzumab (TRZ), is associated with an increased risk of cardiotoxicity.
Little is known on the potential cardioprotective role of renin angiotensin system (RAS) antagonists in the prevention of
DOX+TRZ mediated cardiotoxicity.
Objective: The aim of the study was to determine whether RAS antagonists would be useful in attenuating DOX+TRZ
induced cardiotoxicity.
Methods: A total of 240 C57Bl/6 mice were randomized to prophylactic treatment with placebo, Aliskiren, Perindopril, or
Valsartan for a total of 13 weeks. Within each arm, mice received treatment with either DOX, TRZ, or the combination of
both drugs. Serial murine echocardiography was performed weekly to characterize the degree of cardiovascular
remodeling within each group.
Results: In wild-type (WT) mice treated with DOX+TRZ, LV end diastolic internal diameter (LVID) increased from
3.1 ± 0.2 mm at baseline to 4.6 ± 0.3 mm at week 13 (p < 0.05) and the LV fractional shortening (FS) decreased
from 52 ± 2% at baseline to 26 ± 2% at week 13 (p < 0.05). Prophylactic treatment with Aliskiren, Perindopril, or
Valsartan attenuated the degree of LV cavity dilatation with LVID dimensions of 3.9 ± 0.2 mm, 4.1 ± 0.2 mm, and
4.2 ± 0.1 mm at week 13, respectively (p < 0.05). Similarly, prophylactic treatment with Aliskiren, Perindopril, or
Valsartan was partially cardioprotective with FS of 40 ± 1%, 32 ± 1%, and 33 ± 2% at week 13, respectively (p < 0.05). As
compared to WT mice receiving DOX+TRZ, prophylactic treatment with RAS inhibition was also associated with improved
survival, corroborating the echocardiographic findings.
Conclusion: The cardiotoxic effects of DOX+TRZ were partially attenuated by the prophylactic administration of RAS
antagonists in a chronic murine model of chemotherapy induced cardiac dysfunction.
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As the second leading cause of cancer related deaths in
women, breast cancer constitutes a major health con-
cern. In Canada alone, approximately 22,000 women are
diagnosed with breast cancer each year and over 5,000
die from the disease [1,2]. Anthracyclines, including
Doxorubicin (DOX), are a class of chemotherapeutic
agents with demonstrated efficacy in the breast cancer
setting [3-6]. The clinical utility of DOX is limited,
however, by its inherent cardiotoxicity. The average
incidence of DOX induced heart failure is 5% at a cu-
mulative dose of 400 mg/m2 and increases to 25% with
cumulative doses above 550 mg/m2 [3-6]. In addition
to DOX, Trastuzumab (TRZ), a monoclonal antibody
against the extracellular domain of the human epider-
mal growth factor receptor 2 protein (HER2), is used
in both the adjuvant and metastatic settings of HER2
positive breast cancer [7-12]. The addition of TRZ to
adjuvant chemotherapy in patients with HER2 positive
breast cancer was unequivocally beneficial, facilitating
a 50% decrease in the risk of cancer relapse and a 33%
decrease in mortality [7-12]. Despite its widespread adop-
tion, however, it is now recognized that TRZ potentiates
the cardiotoxic side effects of DOX. Although clinical trials
have reported the risk of developing LV systolic dys-
function following DOX+TRZ treatment to be as great
as 10% [9-11], recent real world studies have indicated
that nearly 1 in 4 women will develop a drug induced
cardiomyopathy, demonstrating the clinical signifi-
cance of this disease [13-17].
Among the potential mechanisms for DOX+TRZ medi-
ated cardiotoxicity, activation of the renin-angiotensin sys-
tem (RAS) has gained recent attention. In an animal model
of chemotherapy induced cardiomyopathy, chronic DOX
administration (1 mg/kg biweekly, for 8 weeks) was associ-
ated with a 2-fold increase in plasma renin activity, the
enzyme responsible for initiating the RAS [18]. In a separ-
ate study, cardiac neurohumoral activation, signified by in-
creased expression of pro-atrial naturetic peptide (ANP)
mRNA, was observed in rabbits treated with 2 mg/kg DOX
[19]. As RAS activation was shown to trigger ANP expres-
sion, these findings suggested that cardiac neurohumoral
activation was mediated through an increase in the RAS
[20]. Finally, in a chronic rat model, a cumulative dose of
420 mg/kg DOX facilitated up-regulation of the angiotensin
II type 1 receptor (AT1R) [21]. Additional studies have
demonstrated the downstream cardiotoxic effects of AT1R
signalling, including stimulation of NADPH oxidase to gen-
erate oxidative stress, and activation of mitogen-activated
protein kinases (MAPKs), responsible for cellular growth,
inflammation, hypertrophy, and apoptosis [22,23].
RAS involvement in the pathophysiology of DOX+TRZ
mediated cardiac dysfunction has raised the question as
to whether the prophylactic use of RAS antagonists couldpotentially mitigate these cardiotoxic effects. Previous
basic science studies have demonstrated that the prophy-
lactic administration of angiotensin converting enzyme
inhibition (ACEI), including Captopril, Enalapril, and Lisi-
nopril, was partially cardioprotective in both acute and
chronic animal models of DOX induced cardiomyopathy
[19,24,25]. In a rabbit model of DOX mediated cardiomy-
opathy, 1 mg/kg/day oral Lisinopril for a total of 10 weeks
attenuated cardiomyocyte loss and ANP mRNA expres-
sion, in comparison to rabbits receiving DOX alone [19].
Furthermore, intragastric administration of Captopril
(10 mg/kg) or Enalapril (2 mg/kg) for 7 days resulted in
a decline in lipid peroxidation, and enzymatic indica-
tors of acute cardiac toxicity in a rat model of DOX in-
duced cardiomyopathy [24]. Little is known, however,
on the utility of antagonizing the RAS pathway in a
hierarchical fashion for the prevention of combined
DOX+TRZ mediated cardiotoxicity.
The objective of the current study was to determine
whether inhibition of the RAS pathway at three distinct
levels, including direct renin inhibition (DRI; Aliskiren),
angiotensin converting enzyme inhibition (ACEI; Peri-
ndopril), and angiotensin receptor blockade (ARB; Val-
sartan) can prevent cardiac dysfunction in a chronic
in vivo model of DOX+TRZ mediated cardiotoxicity.
Methods
Experimental animals
Animal procedures were conducted in accordance with
guidelines published by the Canadian Council on Animal
Care. All procedures, including drug administration and
longitudinal echocardiographic studies, were approved by
the Animal Protocol Review Committee at the University
of Manitoba.
Adult male C57Bl/6 mice, weighing 20–25 g, were ob-
tained from Jackson Laboratories (MA, US). The animals
were housed under controlled environmental conditions,
including temperature, humidity, and lighting. Standard la-
boratory chow and water were provided ad libitum.
Experimental protocol
A total of 240 C57Bl/6 male mice were randomized to
one of the following prophylactic treatment arms: (A)
placebo (saline; n = 60); (B) Aliskiren (50 mg/kg; n = 60);
(C) Perindopril (3 mg/kg; n = 60); or (D) Valsartan
(10 mg/kg; n = 60) (Figure 1). RAS antagonists were ad-
ministered orally by gavage on a daily basis for the entire
study period of 13 weeks. Furthermore, mice from each
prophylactic treatment arm were randomized to one of the
following chemotherapeutic regimens: (i) TRZ (4 mg/kg
weekly, intraperitoneal (i.p.); n = 20); (ii) DOX (4 mg/kg
weekly, i.p.; n = 20); or (iii) DOX+TRZ (n = 20) (Figure 1).
TRZ, DOX, or DOX+TRZ injections were initiated at
week 2, following 2 weeks of prophylactic treatment with a
Figure 1 A total of 240 C57Bl/6 mice were randomized to one of the following prophylactic treatment arms: (A) placebo (saline; n = 60);
(B) Aliskiren (50 mg/kg; n = 60); (C) Perindopril (3 mg/kg; n = 60); or (D) Valsartan (10 mg/kg; n = 60). RAS antagonists were administered
orally on a daily basis for the entire study period of 13 weeks. Furthermore, mice from each prophylactic treatment arm were randomized to one
of the following chemotherapeutic regimens: (i) TRZ (4 mg/kg weekly, intraperitoneal (i.p.); n = 20); (ii) DOX (4 mg/kg weekly, i.p.; n = 20); or
(iii) DOX+TRZ (n = 20).
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(Figure 2). The cumulative doses of DOX or TRZ
achieved were the minimum concentration to induce a
chemotherapy mediated cardiomyopathy, as previously
validated by our group and others [26-28]. Cardiac
function was evaluated over the course of the study via
serial murine echocardiography. Mice were imaged at
baseline and weekly until euthanization at week 13.
Murine echocardiography
In vivo cardiac function was evaluated by serial murine
echocardiography, as previously described [27]. AwakeFigure 2 Timeline for drugs administered to mice in each group. Mice
Perindopril (3 mg/kg) or Valsartan (10 mg/kg) in drinking water daily. Prop
DOX, TRZ and DOX + TRZ and was continued for 13 weeks. DOX (4 mg/kg
weekly intraperitoneal injection for a total of 5 weeks. Cardiac function wamice were imaged at baseline and weekly thereafter, for
the duration of the 13-week study (Figure 2). Images
were captured in M-mode and the 2D parasternal short
axis view, using a 13-MHz linear array ultrasound probe
(Vivid 7, GE Medical Systems, Milwaukee, WI, USA).
M-mode recordings were used to evaluate indices of car-
diac dimension and function: LV end diastolic internal
diameter (LVID), LV end systolic internal diameter
(LVIS), interventricular septal thickness (IVS), posterior
wall thickness (PWT), LV fractional shortening (LVFS),
and LV ejection fraction (LVEF). Echocardiographic im-
ages were processed offline using EchoPAC v110.0.0 PCreceived prophylactic treatment with Aliskiren (50 mg/kg),
hylactic treatment was started 2 weeks prior to chemotherapy with
), TRZ (4 mg/kg) and DOX + TRZ (4 mg/kg) was administered by
s monitored by echocardiography on a weekly basis for 13 weeks.
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WI, US).
A total of 40 mice, from various treatment groups,
were randomly selected in order to assess the variability
associated with echocardiographic measurements of LV
cavity dimensions and function. To determine intra-
observer variability, repeat LVID and LVFS measurements
were made by a single observer (DJ), two weeks apart.
Inter-observer variability was established by comparing
LVID and LVFS values calculated by two independent ob-
servers (NB and DJ). Intra- and inter-observer variability
were reported as the absolute value of the difference be-
tween the two observations divided by the mean.
Statistical analysis
Statistical analysis was conducted using SPSS 15.0 and
GraphPad Prism 5, with echocardiographic data
expressed as a mean ± SD. An analysis of variance ap-
proach for repeated measurements comparison of echo-
cardiographic parameters over time was used. One-way
ANOVA and post-hoc Dunnett’s tests were performed




The overall survival of C57Bl/6 mice administered TRZ,
DOX, or DOX+TRZ, with or without RAS inhibitor prophy-
laxis is represented in Figure 3. In mice treated with TRZ
alone, the survival rate was 100%. The administration of ei-
ther DOX alone or the combination of DOX+TRZ resulted
in survival rates to be significantly reduced to 50% and 30%,
respectively, by the end of the study. Conversely, prophy-
lactic administration of a RAS inhibitor attenuated the in-
creased mortality rates observed with both DOX and
DOX+TRZ therapy. For mice in the DOX treatment arm,
overall survival was significantly increased when pre-
treated with Aliskiren, Perindopril, or Valsartan (p < 0.05).
Similarly, overall survival following DOX+TRZ treatmentFigure 3 Survival probability at the end of 13 weeks for
C57Bl/6 mice receiving prophylactic treatment with RAS
inhibitors Aliskiren, Perindopril or Valsartan and then
treated with anti-cancer drugs TRZ, DOX or the combination
of DOX+TRZ. *p < 0.05 significant as compared to TRZ. #p < 0.05
comparing placebo to either Aliskiren, Perindopril, or Valsartan.was significantly increased by the prophylactic administra-
tion of one of the RAS antagonists (Figure 3).
Echocardiographic indices
Echocardiographic indices, including HR, PWT, LVID,
LVFS, and LVEF were within normal physiologic limits for
all mice at baseline. No significant change from baseline
value was observed for HR or PWT at week 13 in any of
the treatment arms (Table 1). In C57Bl/6 mice treated with
TRZ, there were no significant changes in LV cavity dimen-
sions as compared to baseline (Figure 4A). Mice treated
with DOX alone demonstrated a significant increase in cav-
ity dimensions, as the LVID increased from 3.2 ± 0.1 mm at
baseline to 4.5 ± 0.2 mm at week 13 (p < 0.05, Figure 4B).
Mice receiving DOX+TRZ treatment demonstrated a
similar increase in LVID from 3.1 ± 0.2 mm at baseline
to 4.6 ± 0.3 mm at week 13 (p < 0.05, Figure 4C). Pre-
treatment with Aliskiren, Perindopril, and Valsartan
significantly reduced LVID in mice administered DOX
alone from 4.5 ± 0.2 mm to 3.6 ± 0.2 mm, 3.9 ± 0.2 mm,
and 4.0 ± 0.2 mm, respectively, at week 13 (p < 0.05;
Figure 4B). Similarly, in mice treated with DOX+TRZ,
the prophylactic administration of Aliskiren, Perindo-
pril, and Valsartan significantly reduced LVID at week
13 from 4.6 ± 0.3 mm to 3.9 ± 0.2 mm, 4.1 ± 0.2 mm,
and 4.2 ± 0.1 mm, respectively, (p < 0.05; Figure 4C).
LVFS did not change from baseline values in mice
administered TRZ over the course of the 13 week study
(Figure 5A). In mice treated with DOX alone, LVFS de-
creased from 51 ± 1% at baseline to 32 ± 2% at week 13
(p < 0.05; Figure 5B). Pre-treatment with Aliskiren,
Perindopril, and Valsartan attenuated DOX induced LV
impairment, improving LVFS values to 45 ± 1%, 38 ± 1%,
and 37 ± 2%, respectively, at week 13 (p < 0.05; Figure 5B).
In mice treated with the combination of DOX+TRZ, LVFS
further decreased from 52 ± 2% at baseline to 26 ± 2% at
week 13 (p < 0.05; Figure 5C). Prophylactic treatment with
Aliskiren, Perindopril, and Valsartan significantly improved
LVFS to 40 ± 1%, 32 ± 1%, and 33 ± 2%, respectively, at
week 13 (p < 0.05; Figure 5C). The LVEF values corrobo-
rated the LVFS findings as shown in Figure 6.
Intra- and inter-observer variabilities of LVID and LVFS
parameters are summarized in Table 2. Overall, there was
good to excellent intra- and inter-observer variabilities for
LVID and LVFS measurements.
Discussion
In Canada, breast cancer is the most common female
malignancy and is the second leading cause of cancer
related deaths in women. Despite the widespread use
of DOX+TRZ in breast cancer treatment, efficacy is
limited by the inherent cardiotoxicity of this regimen.
Consequently, cardiac dysfunction has been identified
in approximately 1 in 4 women receiving this anti-
Table 1 Echocardiographic parameters
Echo variable Treatment arm Group Baseline Week 13 p
TRZ 717 ± 12 729 ± 10 0.62
Placebo DOX 725 ± 10 701 ± 18 0.58
DOX+ TRZ 690 ± 14 695 ± 18 0.82
Heart Rate (bpm) TRZ 735 ± 15 740 ± 12 0.88
Aliskiren DOX 705 ± 14 701 ± 21 0.72
DOX+ TRZ 705 ± 14 701 ± 21 0.72
TRZ 705 ± 18 710 ± 12 0.9
Perindopril DOX 722 ± 14 720 ± 18 0.77
DOX+ TRZ 722 ± 14 720 ± 18 0.77
TRZ 744 ± 13 735 ± 12 0.67
Valsartan DOX 695 ± 14 705 ± 12 0.72
DOX+ TRZ 695 ± 14 705 ± 12 0.72
TRZ 0.82 ± 0.02 0.84 ± 0.01 0.92
Placebo DOX 0.83 ± 0.02 0.81 ± 0.01 0.97
DOX+ TRZ 0.84 ± 0.01 0.83 ± 0.01 0.76
TRZ 0.80 ± 0.03 0.83 ± 0.02 0.52
Aliskiren DOX 0.83 ± 0.02 0.81 ± 0.02 0.68
PWT (mm) DOX+ TRZ 0.80 ± 0.04 0.82 ± 0.02 0.82
TRZ 0.81 ± 0.04 0.82 ± 0.02 0.82
Perindopril DOX 0.83 ± 0.02 0.81 ± 0.02 0.58
DOX+ TRZ 0.82 ± 0.04 0.83 ± 0.01 0.76
TRZ 0.82 ± 0.01 0.84 ± 0.01 0.67
Valsartan DOX 0.82 ± 0.03 0.83 ± 0.02 0.72
DOX+ TRZ 0.84 ± 0.02 0.83 ± 0.01 0.76
PWT, posterior wall thickness.
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standing of the potential mechanisms contributing to
DOX+TRZ mediated cardiotoxicity, there is currently
no approved prophylactic therapy to prevent chemo-
therapy induced cardiomyopathy in breast cancer pa-
tients. In the current study, we demonstrated that the
cardiotoxic side effects of DOX+TRZ are partially
attenuated by the prophylactic administration of RAS
antagonists, as characterized by an improvement in
overall survival rate and prevention of adverse cardio-
vascular remodeling.
Several previous studies using murine models have il-
lustrated the significant mortality associated with DOX
administration. Neilan et al. demonstrated a survival rate
of 35% at week 16 in C57Bl/6 mice receiving DOX
(4 mg/kg weekly) for 5 weeks [29]. Similarly, in rats
treated with DOX (4 mg/kg weekly) for 6 weeks, a de-
creased survival rate of 75% was reported at the end of a
10 week study [25]. This present study demonstrated simi-
lar reductions in overall survival (50%) for mice in the
DOX treatment arm at 13 weeks. The effect was even more
pronounced in animals receiving combination therapy withDOX+TRZ. Conversely, prophylactic treatment with RAS
inhibitors provided survival benefits. These basic science re-
sults provide encouraging evidence for the potential use of
RAS antagonists in the prevention of DOX+TRZ me-
diated cardiomyopathy, which warrants further study
in the clinical setting.
In addition to the survival benefits conferred by the
prophylactic administration of RAS inhibitors, there is
an improvement in adverse cardiovascular remodeling in
our chronic DOX+TRZ mediated cardiotoxicity model.
Anthracyclines, including DOX, affect hemodynamic and
echocardiographic parameters, leading to depressed cardiac
function in murine models of chemotherapeutic regimens
[26-29]. In an acute murine model of chemotherapy medi-
ated cardiotoxicity, we previously demonstrated severe LV
systolic dysfunction due to DOX treatment, as exemplified
by LV cavity dilatation and reduced LVEF [26]. The effect
was even more pronounced in animals receiving the
combination of DOX+TRZ, as the LVFS decreased by
14% and the EF decreased by 20% at day 10, as com-
pared to baseline [26]. Similar results were obtained by
Neilan et al. in C57Bl/6 mice treated with a single dose
Figure 4 LVID (mm) in C57Bl/6 mice receiving prophylactic treatment with Aliskiren, Perindopril, Valsartan or placebo prior to
receiving one of the following anti-cancer drugs: A) TRZ; B) DOX; or C) DOX+TRZ. Values were represented as mean ± SD. (*) indicates p < 0.05
as compared to baseline within each group. At baseline, all the groups had n = 20. At the end of 13 weeks, TRZ alone (n = 20); Aliskiren+TRZ (n = 20);
Perindopril+TRZ (n = 20); Valsartan+TRZ (n = 20); DOX alone (n = 10); Aliskiren+DOX (n = 16); Perindopril+DOX (n = 14); Valsartan+DOX (n = 14); DOX+TRZ
(n = 6); Aliskiren+ DOX+TRZ (n = 14); Perindopril+DOX+TRZ (n = 11); and Valsartan+DOX+TRZ (n = 10).
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creased by 17 ± 1% and 13 ± 1% respectively, by day 5
[29]. A chronic study of DOX administration (4 mg/kg
for 5 weeks) performed by the same group, further
demonstrated a reduction in LVFS and EF by 29% and
36%, respectively from baseline value at 16 weeks [29].
Our current study adds to the existing literature by con-
firming the cardiotoxic effects of DOX in a chronic murine
model. Specifically, we demonstrated LV systolic dysfunc-
tion, as illustrated by a reduction in LVFS and LVEF and
concurrent increase in LVID. Furthermore, we demon-
strated the increased cardiotoxic side effect in mice admin-
istered the combination of DOX+TRZ. In accordance with
the aforementioned mortality benefits, RAS inhibition miti-
gated the adverse cardiac remodelling associated with
DOX+TRZ treatment.
Although the pathogenesis of DOX+TRZ mediated car-
diotoxicity is multifactorial, there is accumulating evidence
to suggest the RAS as a key contributor. Angiotensin II
plays an important role as a vasoconstrictor agent and a
mitogenic factor by interacting with the AT1R in cardiovas-
cular myocytes [30]. Although DOX induces myofibrillar
loss, apoptosis, and significantly impairs contractile func-
tion in WT mice, this drug induced cardiotoxicity was notobserved in AT1R-knockout mice or in animals treated
with AT1R blockade [30]. These findings suggest a con-
tributory role for the RAS pathway in the development of
DOX mediated cardiotoxicity. The administration of the
ARB Telmisartan (10 mg/kg/day for 7 days), was cardio-
protective in rats treated with a single dose of 20 mg/kg
DOX, by decreasing lipid peroxidation, GSH depletion,
and oxidative stress [31]. Additionally, in a chronic rat
model of DOX induced cardiotoxicity (DOX 25 mg/kg for
a 6 week period), Enalapril served to preserve mitochon-
drial function, down-regulate free radical production, and
preserve overall cardiac function [25]. Finally, in a chronic
rat model of DOX (15 mg/kg) mediated cardiac dys-
function, the prophylactic administration of either ACEI
(Captopril 60 mg/kg) or ARB (Telmisartan 10 mg/kg)
proved to be cardioprotective [32]. This was evidenced by
a significant reduction in the concentration of cardiac bio-
markers and oxidative stress, and by the maintenance of
characteristic cardiac histology in rats pre-treated with
RAS antagonism. Our current study adds to the existing
literature which supports the cardioprotective capabilities
of RAS antagonism in a chronic murine model of chemo-
therapy induced cardiac dysfunction. Our study is the first
to also demonstrate the potential cardioprotective role of
Figure 5 Fractional shortening of C57Bl/6 mice receiving prophylactic treatment with Aliskiren, Perindopril, Valsartan or placebo prior
to receiving one of the following anti-cancer drugs: A) TRZ; B) DOX; or C) DOX+TRZ. Values were represented as mean ± SD. (*) indicates
p < 0.05 as compared to baseline within each group. At baseline, all the groups had n = 20. At the end of 13 weeks, TRZ alone (n = 20);
Aliskiren+TRZ (n = 20); Perindopril+TRZ (n = 20); Valsartan+TRZ (n = 20); DOX alone (n = 10); Aliskiren+DOX (n = 16); Perindopril+DOX (n = 14);
Valsartan+DOX (n = 14); DOX+TRZ (n = 6); Aliskiren+ DOX+TRZ (n = 14); Perindopril+DOX+TRZ (n = 11); and Valsartan+DOX+TRZ (n = 10).
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DOX mediated cardiotoxicity. Additionally, although previ-
ous animal studies have focussed on a DOX only model
[19,24,25,31,32], we have extended our important findings
to a combined DOX+TRZ model, mimicking the clinical
setting of breast cancer.
Translating these basic science findings to the clinical
arena, a number of clinical studies have evaluated the
potential cardioprotective role of RAS antagonists in the
clinical setting of chemotherapy mediated cardiotoxicity.
Although the administration of ACEI or ARB is associ-
ated with reduced morbidity and mortality in the treat-
ment of heart failure [33], a limited number of clinical
studies have demonstrated the potential benefits of RAS
inhibition in the prevention of DOX mediated cardio-
toxicity. In a small prospective study including 49 patients
with various cancers responsive to an anthracycline based
chemotherapy regimen, Dessi et al. demonstrated that
ARB was able to reverse acute myocardial dysfunction
up to 12 months of follow-up [34]. Cardinale at al.
demonstrated that ACEI can prevent a decline in LVEF
and cardiac events in cancer patients receiving high
dose anthracyclines [35]. In a recent meta-analysis, the
prophylactic administration of ACEI or ARB in patientsreceiving an anthracycline based regimen was associated
with a relative risk of 0.11 for the development of cardio-
toxicity compared to placebo [36]. The recent OVERCOME
trial involved 90 patients with malignant hemopathies, ran-
domized to receive prophylactic ACEI (Enalapril) and beta-
blockers (Carvedilol) at least 24 hours prior to chemother-
apy or to a control group [37]. The results suggested that
combination pre-treatment with Enalapril and Carvedilol
was cardioprotective, as a lower incidence of death, heart
failure and LV systolic dysfunction was observed in the
intervention group. The ongoing MANTICORE study is
similarly investigating the cardioprotective role of angioten-
sin converting enzyme inhibition and beta-blockers in
HER2 positive breast cancer patients treated with TRZ [38].
Patients were randomized to prophylactic ACEI (Perindo-
pril), beta-blocker (Bisoprolol) or placebo, 7 days prior to
TRZ therapy. The MANTICORE study will determine if
DOX+TRZ mediated remodelling and systolic dysfunction
is attenuated by the prophylactic administration of ACEI
and beta-blockers in the clinical setting of breast can-
cer. In our current study, as the cardiotoxic side effects
of DOX+TRZ are partially attenuated by the prophylac-
tic administration of RAS antagonists, in particular by
DRI as compared to either ACEI or ARB, future clinical
Figure 6 LV ejection fraction (LVEF) of C57Bl/6 mice receiving prophylactic treatment with Aliskiren, Perindopril, Valsartan or drinking
water prior to receiving one of the following anti-cancer drugs: A) TRZ; B) DOX; or C) DOX+TRZ. Values were represented as mean ± SD.
(*) indicates p < 0.05 as compared to baseline within each group. At baseline, all the groups had n = 20. At the end of 13 weeks, TRZ alone (n = 20);
Aliskiren+TRZ (n = 20); Perindopril+TRZ (n = 20); Valsartan+TRZ (n = 20); DOX alone (n = 10); Aliskiren+DOX (n = 16); Perindopril+DOX (n = 14);
Valsartan+DOX (n = 14); DOX+TRZ (n = 6); Aliskiren+ DOX+TRZ (n = 14); Perindopril+DOX+TRZ (n = 11); and Valsartan+DOX+TRZ (n = 10).
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in the breast cancer setting are warranted.
There were some limitations to our study. First, al-
though both DOX+TRZ were co-administered on a
weekly basis to produce a chronic murine model of
chemotherapy induced cardiotoxicity, adjuvant therapy
with TRZ should ideally be given after treatment with an
anthracycline based chemotherapy regimen to mimic the
clinical setting of breast cancer. Second, although AliskirenTable 2 Intra- and inter-observer variabilities of the
echocardiographic parameters
Echocardiographic parameters Mean difference ± SD
Intra-observer variability
LVID (mm) 0.05 ± 0.02
LVFS (%) 0.6 ± 0.2
Inter-observer variability
LVID (mm) 0.08 ± 0.04
LVFS (%) 1.3 ± 0.2
LVID, Left ventricular end diastolic internal diameter; LVFS, Left ventricular
fractional shortening.is commonly used as a primary treatment agent for hyper-
tension, recent randomized controlled trials, including the
ASTRONAUT study, have failed to demonstrate a benefit
of DRI in reducing overall morbidity and mortality in the
heart failure setting [39]. In the current study, we demon-
strated that Aliskiren may be more cardioprotective as
compared to ACEI and ARB, suggesting a need for a clin-
ical study to further evaluate this hypothesis generating
finding in the Cardio-Oncology population. Finally, future
mechanistic studies focusing on oxidative stress and apop-
tosis are required to understand the potential cardiprotec-
tive effects of the various RAS antagonists in the setting of
DOX+TRZ mediated cardiotoxicity.
Conclusions
The cardiotoxic effects of DOX+TRZ were partially at-
tenuated by the prophylactic administration of RAS an-
tagonists in a chronic murine model of chemotherapy
induced cardiac dysfunction.
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